Hemang Dave, M.D.
NPI 1891782371 · Hematology & Oncology Physician · Marmora, NJ
Enrolled with Medicare as Practitioner - Hematology/Oncology · source: CMS PECOS Public Provider Enrollment (2026.04.01)
Provider details
- NPI number
- 1891782371
- Entity type
- Individual
- Primary specialty
- Hematology & Oncology PhysicianAllopathic & Osteopathic Physicians
- Credential
- M.D.
- Sex
- Male
- Sole proprietor
- No
- License
- MA059378 (NJ)
Specialties & taxonomies
Allopathic & Osteopathic Physicians
Profile Score
A profile completeness & documented-activity index — NOT a quality, outcomes, or patient-satisfaction rating.
- Registry tenure25% of score
20 yrs in NPPES registry
- Profile completeness25% of score
100% of core fields populated
- Practice footprint15% of score
1 documented practice location
- Medicare service volume (vs. specialty peers)25% of score
6,305 Medicare services, 2024 (ranked within specialty)
- Open Payments transparency10% of score
Has Open Payments disclosures (2024)
Medicare volume is ranked against active providers in the same specialty. Signals a provider has no public data for (e.g. Medicare claims) are left out of the score entirely — never counted as zero — so providers without that data are not penalized. See the full formula and weights in our .
What this provider does (Medicare)
Based on Medicare fee-for-service claims, 2024; not all care is captured.
| Service (HCPCS) | Medicare services | Typical Medicare-allowed (2024) |
|---|---|---|
| Complete Blood Cell Count (red Cells, White Blood Cell, Platelets), Automated Test and Automated Differential White Blood Cell Count85025 | 1,272 | $8 |
| Insertion of Needle Into Vein for Collection of Blood Sample36415 | 1,178 | $9 |
| Established Patient Office Or Other Outpatient Visit With Moderate Level of Decision Making, If Using Time, 30 Minutes Or More99214 | 541 | $135 |
| Infusion Into a Vein for Therapy, Prevention, Or Diagnosis, Additional Sequential Infusion, 1 Hour Or Less96367 | 416 | $30 |
| Injection of Drug Or Substance Under Skin Or Into Muscle96372 | 412 | $15 |
| Visit Complexity Inherent to Evaluation and Management Associated With Medical Care Services That Serve As the Continuing Focal Point for All Needed Health Care Services And/Or With Medical Care Services That Are Part of Ongoing Care Related to a Patient'S |
What this provider prescribes (Medicare Part D)
Top drugs by Medicare Part D claim volume, 2024 · 21 distinct drugs on file.
| Drug | Part D claims (2024) | Beneficiaries |
|---|---|---|
| Apixabanbrand: Eliquis | 77 | 23 |
| Warfarin Sodium | 77 | 19 |
| Tamoxifen Citrate | 50 | 16 |
| Ibrutinibbrand: Imbruvica | 50 | — |
| Letrozole | 45 | 13 |
| Lenalidomidebrand: Revlimid | 34 | — |
| Raloxifene Hcl | 29 | — |
Transparency — industry payments
Based on CMS Open Payments, 2024; not all care is captured.
$2,507 across 119 records (Open Payments 2024)
Open Payments discloses payments and transfers of value (meals, travel, consulting, research, royalties) from drug and device makers to providers. This is a transparency signal, not a verdict — such payments are legal and common, and their presence is neither an endorsement nor a criticism. Source: CMS Open Payments, program year 2024.
Practice location
Mailing address
Registry dates
- Enumerated
- 2005-09-30
- Last updated
- 2011-03-10
Source: CMS NPPES Data Dissemination (June 2026). NPI Central is not affiliated with CMS. Data is provided as-is from the public registry.